The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS).
The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.

开始日期2025-10-01

申办/合作机构

Emory University

[+1]

NCT05797805

/ Recruiting临床1/2期

A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma

This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The second part of the study will begin with a brief dose escalation part for each combination (tegavivint plus cabozantinib or tegavivint plus lenvatinib) followed by a combination dose expansion.

开始日期2023-09-13

申办/合作机构

Iterion Therapeutics, Inc.

NCT05755087

/ Recruiting临床1期IIT

Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.

开始日期2023-03-06

申办/合作机构

Ohio State University Comprehensive Cancer Center

100 项与 Tegatrabetan 相关的临床结果

登录后查看更多信息

100 项与 Tegatrabetan 相关的转化医学

登录后查看更多信息

100 项与 Tegatrabetan 相关的专利（医药）

登录后查看更多信息

项与 Tegatrabetan 相关的文献（医药）

2025-12-01·Nature Chemical Biology

Tegavivint triggers TECR-dependent nonapoptotic cancer cell death

Article

作者: Bensinger, Steven J ; Nathanson, David A ; Moffat, Jason ; Moding, Everett J ; Decosto, Cassandra M ; Rees, Matthew G ; Chan, Alyssa A ; Joseph, Alby J ; Myers, Chad L ; Johnson, Brianna ; Roth, Jennifer A ; Chitkara, Shweta ; Manukian, Sophia ; Boone, Charles ; Ko, Pin-Joe ; Atilla-Gokcumen, G Ekin ; Skouta, Rachid ; Leak, Logan ; Ritho, Joan ; Ronan, Melissa M ; Magtanong, Leslie ; Wang, Ziwei ; Millner, Alec ; Dixon, Scott J ; Lee, Weaverly Colleen ; Salinas, Jennifer J

Small molecules that induce nonapoptotic cell death are of fundamental mechanistic interest and may be useful to treat certain cancers. Here we report that tegavivint, a drug candidate undergoing human clinical trials, can activate a unique mechanism of nonapoptotic cell death in sarcomas and other cancer cells. This lethal mechanism is distinct from ferroptosis, necroptosis and pyroptosis and requires the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase (TECR). TECR is canonically involved in the synthesis of very-long-chain fatty acids but appears to promote nonapoptotic cell death in response to CIL56 and tegavivint via the synthesis of the saturated long-chain fatty acid palmitate. These findings outline a lipid-dependent nonapoptotic cell death mechanism that can be induced by a drug candidate currently being tested in humans.

2025-04-22·Blood Advances

Targeting the DNA damage response through TBL1X in mantle cell lymphoma

Article

作者: Pray, Betsy ; Koirala, Shirsha ; Carvajal-Moreno, Jessika ; Tsyba, Liudmyla ; Jindal, Udita ; Alinari, Lapo ; Yalowich, Jack ; Nishat, Shamama ; Jain, Neeraj ; Sehgal, Lalit ; Leon, Sydney ; Barta, Brian ; Hout, Ian ; Baiocchi, Robert A. ; Singh, Satishkumar ; Baiocchi, Ethan ; Hinterschied, Claire ; Chan, Wing Keung ; Hanel, Walter

Abstract:

Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma characterized by significant genomic instability. Patients with MCL who progress on targeted therapies have a short survival; thus, novel therapeutic strategies are urgently needed. Overexpression of transducin β-like protein 1 X-linked (TBL1X) has been documented in several types of cancer and associated with poor prognosis. TBL1X is a critical regulator of multiple oncogenic networks; however, its function in MCL has not been explored. Our data show that, unlike normal B cells, MCL cells express abundant levels of TBL1X and that genetic knockdown of TBL1X and treatment with tegavivint (Iterion), a first-in-class small molecule targeting TBL1X, promote MCL cell death in vitro and in vivo. Moreover, TBL1X controls the stability of key MCL oncogenic drivers, cyclin D1 and RAD51; and targeting TBL1X results in significant DNA damage, cell cycle arrest, and ultimately cell death. Combining tegavivint with poly(adenosine 5′-diphosphate-ribose) polymerase-1/2 inhibitor talazoparib results in synergistic MCL cell death in vitro, and in vivo this combination significantly prolongs the survival of a patient-derived MCL xenograft. Together, our results define the role of TBL1X in maintaining genomic stability in MCL and establish targeting TBL1X as a novel therapeutic strategy for patients with this incurable disease.

2024-03-01·Leukemia

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Article

作者: Das, Kaberi ; Bhalla, Kapil N ; Sharma, Sunil ; DiNardo, Courtney D ; Pemmaraju, Naveen ; Kadia, Tapan M ; Ruan, Xinjia ; Horrigan, Stephen ; Fiskus, Warren ; Borthakur, Gautam ; Birdwell, Christine E ; Su, Xiaoping ; Khoury, Joseph D ; Mill, Christopher P ; Sasaki, Koji ; Kantarjian, Hagop ; Daver, Naval ; Davis, John A

AML with chromosomal alterations involving 3q26 overexpresses the transcription factor (TF) EVI1, associated with therapy refractoriness and inferior overall survival in AML. Consistent with a CRISPR screen highlighting BRD4 dependency, treatment with BET inhibitor (BETi) repressed EVI1, LEF1, c-Myc, c-Myb, CDK4/6, and MCL1, and induced apoptosis of AML cells with 3q26 lesions. Tegavivint (TV, BC-2059), known to disrupt the binding of nuclear β-catenin and TCF7L2/LEF1 with TBL1, also inhibited co-localization of EVI1 with TBL1 and dose-dependently induced apoptosis in AML cell lines and patient-derived (PD) AML cells with 3q26.2 lesions. TV treatment repressed EVI1, attenuated enhancer activity at ERG, TCF7L2, GATA2 and MECOM loci, abolished interactions between MYC enhancers, repressing AML stemness while upregulating mRNA gene-sets of interferon/inflammatory response, TGF-β signaling and apoptosis-regulation. Co-treatment with TV and BETi or venetoclax induced synergistic in vitro lethality and reduced AML burden, improving survival of NSG mice harboring xenografts of AML with 3q26.2 lesions.

项与 Tegatrabetan 相关的新闻（医药）

2025-08-02

·ioncology

2025 WCLC | 摘要速递——壁报导览入选研究一览！

点上方蓝字“ioncology”关注我们，然后点右上角“…”菜单，选择“设为星标”由国际肺癌研究协会（IASLC）主办的 2025年世界肺癌大会（WCLC 2025）将于2025年9月6日至9日在西班牙巴塞罗那举行。作为肺癌及其他胸部恶性肿瘤领域全球领先的多学科肿瘤学盛会，WCLC致力于传递该领域最前沿的诊疗进展，为世界各地的专家学者及研究者提供分享前沿研究成果、促进合作交流的平台。近日，WCLC官网已披露了除LBA外的大会入选研究标题。其中，壁报导览（poster tour）部分共设17个专场，涵盖70余项研究。《肿瘤瞭望》对入选壁报导览的研究标题进行整理，以飨读者。PT1.01-风险因素、风险降低与烟草控制摘要号：PT1.01.01英文标题：Large Language Models to Extract Smoking History From Clinical Notes in EHR to Evaluate Lung Cancer Surveillance Strategies中文标题：大型语言模型从 EHR 临床记录中提取吸烟史，以评估肺癌监测策略讲者：I. Luo（美国）摘要号：PT1.01.02英文标题：Temporal Analysis of Smoking Profiles in Brazil Among Lung Cancer Patients and the Impact of 25 Years of Public Policies中文标题：巴西肺癌患者吸烟状况的时间分析及25年公共政策的影响讲者：Bruna Rezende（巴西）PT1.02-肿瘤生物学 - 临床前生物学摘要号：PT1.02.01英文标题：Targeting NOX1/4-YAP/TEAD-CD47 Axis Promotes Macrophage Phagocytosis and Potentiates Radiotherapy Antitumor Efficacy in NSCLC中文标题：靶向NOX1/4-YAP/TEAD-CD47轴促进巨噬细胞吞噬功能并增强放射治疗在非小细胞肺癌中的抗肿瘤疗效讲者：董晓荣教授（华中科技大学同济医学院附属协和医院）?摘要号：PT1.02.02英文标题：Novel Organoid Models of Patient-Derived Lung Cancer in Decellularized Mouse Lung Tissue中文标题：脱细胞小鼠肺组织中患者来源肺癌的新型类器官模型讲者：R. Navab（加拿大）摘要号：PT1.02.03英文标题：GBC-11004: An AI-Driven Novel Kinase Target With Potential to Overcome Osimertinib Resistance in NSCLC中文标题：GBC-11004：一种人工智能驱动的新型激酶靶点，有望克服非小细胞肺癌中奥希替尼的耐药性讲者：J. Ryu（韩国）摘要号：PT1.02.04英文标题：Mapping Gene-Environment Interactions Driving Small Cell Lung Cancer (SCLC) Initiation in Human Airway Organoids中文标题：绘制人类气道类器官中驱动小细胞肺癌（SCLC）发生的基因-环境相互作用图谱讲者：A. Marco（西班牙）PT1.03-肿瘤生物学 - 转化生物学摘要号：PT1.03.01英文标题：Precision Medicine Platform to Guide the Treatment of NSCLC中文标题：精准医疗平台指导非小细胞肺癌治疗讲者：S.D. Merajver（美国）摘要号：PT1.03.02英文标题：Single-Cell Profiling of Tumor Lineage Plasticity and the Immune Microenvironment in Transformed Small Cell Lung Cancer中文标题：转化型小细胞肺癌中肿瘤谱系可塑性及免疫微环境的单细胞分析讲者：黄婕教授（广东省人民医院）摘要号：PT1.03.03英文标题：Drug Repurposing for Metastatic Lung Adenocarcinoma Therapy Using AI-Guided Single-Cell Gene Expression Profiles中文标题：利用人工智能引导的单细胞基因表达谱进行转移性肺腺癌药物再利用治疗讲者：Maria Raquel Fernandes（巴西）摘要号：PT1.03.04英文标题：VIKTOR - the Virtual International Knowledgebase for Thoracic Oncology Research of the IASLC中文标题：VIKTOR——IASLC胸部肿瘤学研究虚拟国际知识库讲者：F. Cerciello（瑞士）摘要号：PT1.03.05英文标题：An Ai-Based Predictive Tool for Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data中文标题：基于人工智能的肺癌药物突变预测工具，利用全国综合基因组分析数据讲者：H. Ikushima（日本）PT1.04-筛查与早期检测摘要号：PT1.04.01英文标题：Incidental Pulmonary Nodule Programs (IPN) Working Together With LDCT Scans and Artificial Intelligence (AI) Increase Lung Cancer Detection中文标题：偶发性肺结节项目 (IPN) 与 LDCT 扫描和人工智能 (AI) 协同作用，提高肺癌检测率讲者：Luis Raez（美国）摘要号：PT1.04.02英文标题：Performance of Lung Nodule and Cancer Risk Calculators in Identifying Primary Lung Cancer Across Screening and Incidental Nodule Populations中文标题：肺结节和癌症风险计算器在筛查和偶然结节人群中识别原发性肺癌的表现讲者：F.A.C. Sarmento Neto（葡萄牙）摘要号：PT1.04.03英文标题：The LEAP Study: A Biospecimen Bank for Validation of Liquid Biomarkers in a Lung Cancer Screening Cohort中文标题：LEAP 研究：用于验证肺癌筛查队列中液体生物标志物的生物样本库讲者：E. Ostrin（美国）摘要号：PT1.04.04英文标题：Biomarker-Based Eligibility for Lung Cancer Screening - Validation of Protein-Based INTEGRAL-Risk Model in the LC3 Consortium中文标题：基于生物标志物的肺癌筛查资格——LC3联盟中基于蛋白质的INTEGRAL风险模型的验证讲者：M. Johansson（法国）摘要号：PT1.04.05英文标题：Subclassification of Abnormal Cells Into Precancerous and Malignant Categories Based on 3D Cellular Imaging中文标题：基于 3D 细胞成像将异常细胞细分为癌前和恶性类别讲者：Michael Meyer（美国）PT1.05-肺病学与分期摘要号：PT1.05.01英文标题：Impact of Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy on Next-Generation Sequencing中文标题：支气管内超声引导下结内钳活检对下一代测序的影响讲者：K. Sato（日本）摘要号：PT1.05.02英文标题：Development of an AI Image Analysis System for Malignancy Classification in Rapid On-Site Cytologic Evaluation of Lung Cancer中文标题：开发用于肺癌快速现场细胞学评估的恶性肿瘤分类人工智能图像分析系统讲者：T. Sakai（日本）摘要号：PT1.05.03英文标题：Comparison Between Lymph Node Station- and Zone-Based Classification: Analysis With the 9th IASLC Node Descriptors in Surgically Resected NSCLC中文标题：淋巴结站位分类与区域分类的比较：使用第 9 版 IASLC 淋巴结描述符对手术切除的非小细胞肺癌进行分析讲者：S. Kim（韩国）摘要号：PT1.05.04英文标题：Use of an Ultrathin Bronchoscope With a Larger Working Channel Enhances Diagnostic Yield in Cone-Beam CT-Guided Transbronchial Biopsy中文标题：使用具有更大工作通道的超细支气管镜可提高锥形束 CT 引导下经支气管活检的诊断率讲者：N. Kawakita（日本）PT1.06-病理学与生物标志物摘要号：PT1.06.01英文标题：ERBB2 (HER2) Fusions in Lung Cancer Are Targetable by Anti-HER2 Small Molecules and Antibody-Drug Conjugates中文标题：抗 HER2 小分子和抗体-药物偶联物可靶向肺癌中的 ERBB2 (HER2) 融合讲者：M. Ladanyi（美国）摘要号：PT1.06.02英文标题：Distinct Bronchoalveolar Lavage Fluid Microbiome and Metabolome Profiles in EGFR-Mutated and Wild-Type Non-Small Cell Lung Cancer中文标题：EGFR突变型和野生型非小细胞肺癌患者支气管肺泡灌洗液微生物组和代谢组特征不同讲者：L. Wu（广东省人民医院）摘要号：PT1.06.03英文标题：Loss of MTAP Expression in Thymic Carcinomas: Insights From a Retrospective Multi-Institutional, Global Study中文标题：胸腺癌中MTAP表达的缺失：一项回顾性多机构全球研究的见解讲者：Anja Roden（美国）摘要号：PT1.06.04英文标题：Signatures of Functional CD8 T, Marginal Zone/Memory B and NK Cells in PBMCpredict Survivalin NSCLC Patients Receiving Chemoimmunotherapy中文标题：PBMC 中的功能性 CD8 T 细胞、边缘区/记忆 B 细胞和 NK 细胞特征可预测接受化学免疫治疗的 NSCLC 患者的生存率讲者：王杰教授（复旦大学附属肿瘤医院）摘要号：PT1.06.05英文标题：Enhancing Spread Through Air Spaces Diagnosis Using AI Diagnostician: A Multi-Center Study中文标题：使用人工智能诊断专家增强气腔传播诊断：一项多中心研究讲者：H. Wu（广东省人民医院）PT1.07-早期非小细胞肺癌摘要号：PT1.07.01英文标题：IASLC Multidisciplinary Recommendations for Pathological Response Evaluation of Resected Lymph Nodes After Neoadjuvant Therapy in NSCLC中文标题：IASLC 关于非小细胞肺癌新辅助治疗后淋巴结切除病理反应评估的多学科建议讲者：Sabina Berezowska（瑞士）摘要号：PT1.07.02英文标题：Neoadjuvant Ensartinib for ALK-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Real-World Study中文标题：恩沙替尼新辅助治疗ALK阳性（ALK+）非小细胞肺癌（NSCLC）：一项多中心、真实世界研究讲者：张曦教授（陕西省肿瘤医院）摘要号：PT1.07.03英文标题：Adjuvant Osimertinib in Ib-Iiib NSCLC With Uncommon EGFR Mutations (Admin) :Mutation Profileand ctDNA Dynamics中文标题：奥希替尼辅助治疗在Ib-IIIb期非小细胞肺癌中伴罕见EGFR突变（Admin）：突变谱和ctDNA动态讲者：C. Liu（四川大学华西医院）摘要号：PT1.07.04英文标题：Radiomics Model Based on Synthesized PET for Predicting Neoadjuvant Therapy Pathologic Response in NSCLC (CPT-LC-NeoiO Trial)中文标题：基于合成PET预测非小细胞肺癌新辅助治疗病理反应的放射组学模型（CPT-LC-NeoiO试验）讲者：M. Weng（广东省人民医院）PT1.08-局部区域性非小细胞肺癌摘要号：PT1.08.01英文标题：Neoadjuvant Almonertinib Followed by Chemo-Immunotherapy in II-IIIB EGFR-TKI, Interim Analysis of a Single Arm, Phase II Study (NEOVADE)中文标题：II-IIIB期EGFR-TKI敏感突变非小细胞肺癌患者的新辅助阿美替尼序贯化疗-免疫治疗：一项单臂 II 期研究（NEOVADE）的中期分析讲者：林俊涛教授（广东省人民医院）摘要号：PT1.08.02英文标题：5-Y Outcomes of Stereotactic Ablative Radiotherapy in 101 Unresectable La-Nsclc Patients:The START-NEW-ERA Phase II Trial中文标题：101例无法切除的La-NSCLC患者立体定向消融放射治疗的5年结果：START-NEW-ERA II期临床试验讲者：F. ARCIDIACONO（意大利）摘要号：PT1.08.03英文标题：Chemoradiation/Immunotherapy(IO) for Stageiii NSCLC: Timing of IO, and the Benefits/Selection in Elderly & Black Patients中文标题：III 期非小细胞肺癌的放化疗/免疫治疗（IO）：免疫治疗的时机及在老年和黑人患者中的获益/选择讲者：J. Varlotto（美国）摘要号：PT1.08.04英文标题：Cachexia in Patients With Unresectable Stage III NSCLC中文标题：无法切除的 III 期非小细胞肺癌患者的恶病质讲者：C. Muñoz-Pinedo（西班牙）摘要号：PT1.08.05英文标题：Radioresistance of NSCLC Tumors Is Mediated by Immunosuppressive Cell Populations. Strategies to Sensitize Tumors by Targeting Innate Immunity中文标题：非小细胞肺癌（NSCLC）肿瘤的放射抗性由免疫抑制细胞群介导：靶向先天免疫的肿瘤敏感化策略讲者：S. León（西班牙）PT1.09-转移性非小细胞肺癌 - 局部治疗摘要号：PT1.09.01英文标题：Chemoradiotherapy Plus Tislelizumab in Advanced or Metastatic NSCLC: A Prospective, Multicenter, Phase II Study中文标题：放化疗联合替雷利珠单抗治疗晚期或转移性非小细胞肺癌：一项前瞻性、多中心、II 期研究讲者：林盛教授（西南医科大学附属医院）摘要号：PT1.09.02英文标题：Double Lung Transplantation in Patients With Metastatic Lung-Limited Non-Small Cell Lung Carcinoma (NSCLC): A Case Series中文标题：转移性肺局限性非小细胞肺癌（NSCLC）患者的双肺移植：病例系列讲者：Y.K. Chae（美国）摘要号：PT1.09.03英文标题：Dormant Tumor Maintenance and Immune Evasion in Induced Oligometastatic Lung Cancer中文标题：诱导性寡转移性肺癌中的休眠肿瘤维持和免疫逃避讲者：傅睿教授（广东省人民医院）摘要号：PT1.09.04英文标题：Incomplete Cryoablation Promotes Recurrence and Progression of KRAS-Driven Lung Adenocarcinoma via the NF?B-CCL20-MAPK/MEK/ERK Axis中文标题：不完全冷冻消融通过 NF?B-CCL20-MAPK/MEK/ERK 轴促进 KRAS 驱动的肺腺癌复发和进展讲者：刘泽毅教授（苏州大学附属第一医院）摘要号：PT1.09.05英文标题：Preclinical Safety Assessment of a Conformable Electrode for Bronchoscopy-Guided Radiofrequency Ablation中文标题：支气管镜引导射频消融适形电极的临床前安全性评估讲者：M.J. Kim（韩国）PT2.10-转移性非小细胞肺癌 - 抗体药物偶联物和细胞毒性治疗摘要号：PT2.10.01英文标题：Incidence and Severity of Interstitial Lung Disease Associated With Antibody-Drug Conjugates in NSCLC and SCLC: A Meta-Analysis中文标题：非小细胞肺癌和小细胞肺癌中抗体-药物偶联物相关间质性肺疾病的发病率和严重程度：一项荟萃分析讲者：R. Borea（美国）摘要号：PT2.10.02英文标题：Peripheral Neuropathy and Efficacy of Telisotuzumab Vedotin in c-Met Protein-Overexpressing NSCLC: LUMINOSITY Study中文标题：周围神经病变及 Telisotuzumab Vedotin 在 c-Met 蛋白过表达 NSCLC 中的疗效：LUMINOSITY 研究讲者：Hidehito Horinouchi（日本）摘要号：PT2.10.03英文标题：Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study中文标题：抗PD-L1抗体偶联药物HLX43在晚期/转移性实体瘤中的安全性、耐受性及初步疗效：一项I期临床研究讲者：王洁教授（中国医学科学院肿瘤医院）PT2.11-转移性非小细胞肺癌 - 免疫治疗摘要号：PT2.11.01英文标题：Predictors of Response to PD-(L)1 Blockade in Patients With Oncogene-Driver Negative NSCLC Without History of Tobacco Use中文标题：无吸烟史的致癌基因驱动阴性非小细胞肺癌患者对 PD-(L)1 阻断疗法疗效的预测因素讲者：E. Gariazzo（美国）摘要号：PT2.11.02英文标题：Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Metastatic NSCLC Patients: the RECLAIM study中文标题：转移性非小细胞肺癌患者抗PD-1疗法失败后，放射治疗和抗CTLA4/PD-1疗法的挽救：RECLAIM研究讲者：E.B. Ulas（荷兰）摘要号：PT2.11.03英文标题：Phase I Study of Trametinib, Anlotinib, and Tislelizumab in KRAS-Mutant NSCLC: Safety, RP2D, and Preliminary Efficacy中文标题：曲美替尼、安罗替尼和替雷利珠单抗治疗 KRAS 突变型 NSCLC 的 I 期研究：安全性、RP2D 和初步疗效讲者：韩宝惠教授（上海市胸科医院）摘要号：PT2.11.04英文标题：Divergent Mechanisms of Hyper-Progressive Disease in Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors中文标题：免疫检查点抑制剂治疗非小细胞肺癌中超进展性疾病的不同机制讲者：S. Shim（韩国）摘要号：PT2.11.05英文标题：IFI6-High Cancer-Associated Fibroblasts Impede Immunotherapy Response in NSCLC中文标题：IFI6高水平癌症相关成纤维细胞阻碍非小细胞肺癌的免疫治疗反应讲者：林立教授（南方医科大学南方医院)PT2.12-转移性非小细胞肺癌 - 靶向治疗治疗摘要号：PT2.12.01英文标题：Osimertinib Combined With Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients With Metastatic EGFR-Mutated NSCLC中文标题：奥希替尼联合 Tegavivint 作为转移性 EGFR 突变 NSCLC 患者的一线治疗方案安全且耐受性良好讲者：R. Memmott（美国）摘要号：PT2.12.02英文标题：Effect of JIN-A02, a Novel 4Th-Generation EGFR-TKI, on Multiple EGFR Mutations in Comparison With 3Rd-Generation EGFR-TKIs中文标题：新型第四代EGFR-TKI JIN-A02对多种EGFR突变的疗效及与第三代EGFR-TKI的比较讲者：H-Y. Kim（韩国）摘要号：PT2.12.03英文标题：Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1中文标题：Zongertinib 治疗基线时患有既往接受过 HER2 突变型 NSCLC 治疗且存在脑转移的患者：Beamion LUNG-1讲者：Gerrina Ruiter（荷兰）摘要号：PT2.12.04英文标题：Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs中文标题：奥希替尼 + 赛沃替尼治疗 EGFRm 晚期 NSCLC 伴 MET 过度表达和/或奥希替尼治疗后进展：SAVANNAH 优点讲者：Silvia Novello（意大利）PT2.13-小细胞肺癌和神经内分泌肿瘤摘要号：PT2.13.01英文标题：A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC中文标题：卡瑞利珠单抗联合化疗序贯放化疗及巩固治疗局限期 SCLC 的 II 期临床试验讲者：D. Liu（上海市肺科医院）摘要号：PT2.13.02英文标题：Multi-Cycle Low-Dose Radiotherapy Reshapes Immunochemotherapy for ES-SCLC: The SPUR Phase II Trial中文标题：多周期低剂量放疗重塑ES-SCLC免疫化疗：SPUR II期临床试验讲者：Z. Yao（四川大学华西医院）摘要号：PT2.13.03英文标题：Spatial Multiomics Profiling Reveals Distinct Tumor Microenvironment and Therapeutic Targets in EGFR-Mutant NSCLC Transformed to SCLC中文标题：空间多组学分析揭示EGFR突变NSCLC转化为SCLC时不同的肿瘤微环境和治疗靶点讲者：B. Zhang（美国）摘要号：PT2.13.04英文标题：Real-World Multi-Institution Analysis of Patients With Small Cell Lung Cancer Treated With Tarlatamab中文标题：接受 Tarlatamab 治疗的小细胞肺癌患者的真实世界多机构分析讲者：Alissa Cooper（美国）PT2.14-间皮瘤、胸腺瘤及其他胸部肿瘤摘要号：PT2.14.01英文标题：SYSTEMS-2: A Randomised Phase II Study of Radiotherapy Dose Escalation in Pleural Mesothelioma中文标题：SYSTEMS-2：胸膜间皮瘤放射治疗剂量递增的随机 II 期研究讲者：I. Phillips（英国）摘要号：PT2.14.02英文标题：Human- and AI- Whole Slide Image Assessment of Tumor Immune Microenvironment of Pleural Mesothelioma in Prediction of Patients Outcome中文标题：人类和人工智能全切片图像评估胸膜间皮瘤肿瘤免疫微环境以预测患者预后讲者：G. Maggioni（意大利）摘要号：PT2.14.03英文标题：Molecular Correlates of Response to Atezolizumab Plus Carboplatin and Paclitaxel in Patients With Thymic Carcinoma中文标题：胸腺癌患者对阿替利珠单抗联合卡铂和紫杉醇治疗反应的分子相关性讲者：Y. Shirai（日本）摘要号：PT2.14.04英文标题：Efficacy and Safety of Adebrelimab Plus Chemotherapy as Neoadjuvant Treatment for Unresectable Locally Advanced Thymic Carcinoma中文标题：Adebrelimab联合化疗作为不可切除局部晚期胸腺癌新辅助治疗的疗效和安全性讲者：许宁教授（上海交通大学附属胸科医院）摘要号：PT2.14.05英文标题：Redefining Clinical Outcomes for Peritoneal Mesothelioma (PeM) in the Era of Immunotherapy中文标题：重新定义免疫治疗时代的腹膜间皮瘤 (PeM) 临床疗效讲者：Y. Takabe（美国）PT2.15-多学科护理：护理、辅助医疗和姑息治疗摘要号：PT2.15.01英文标题：A Randomized Controlled Trial on the Effect of Oncologist’s Recommendations on Exercise, Sedentary, and Quality of Life in Patients With NSCLC中文标题：一项关于肿瘤医生建议对非小细胞肺癌患者运动、久坐和生活质量影响的随机对照试验讲者：A. Avancini（意大利）摘要号：PT2.15.02英文标题：Young Lung Cancer: The Psychosocial Needs Assessment中文标题：青年肺癌：心理社会需求评估讲者：Narjust Florez（美国）摘要号：PT2.15.03英文标题：Examining the Role of Frailty Assessments in Older Adult With Lung Cancer to Identify Patient Vulnerabilities and Exploring Patient Outcomes中文标题：探讨虚弱评估在老年肺癌患者中的作用，以识别患者的脆弱性并探索患者的预后讲者：P.N. Papayanis（美国）摘要号：PT2.15.04英文标题：Impact of Physical Exercise on Quality of Life in Patients With Advanced Lung Cancer中文标题：体育锻炼对晚期肺癌患者生活质量的影响讲者：A. López Martín（西班牙）PT2.16-患者权益倡导摘要号：PT2.16.01英文标题：Current Patient, Caregiver and Provider Attitudes Toward Use of AI in Lung Cancer Patient Navigation中文标题：当前患者、护理人员和提供者对肺癌患者导航中使用人工智能的态度讲者：Courtney Granville （美国）摘要号：PT2.16.02英文标题：Patients Who Reach Clinical Trials and Those Who Do Not,A Structural Analysis of Access Disparities in Japan中文标题：参加临床试验的患者与未参加临床试验的患者——日本获取差异的结构分析讲者：Kazuo Hasegawa （日本）摘要号：PT2.16.03英文标题：Overcoming Lung Cancer Nihilism and Fatalism to Foster Compassion, Empathy, and Support中文标题：克服肺癌虚无主义和宿命主义，培养同情心、同理心和支持讲者：Jamie Studts（美国）摘要号：PT2.16.04英文标题：Advancing Lung Cancer Advocacy in Low- and Middle-Income Countries中文标题：推动中低收入国家的肺癌宣传讲者：C. Egwuenu（尼日利亚）摘要号：PT2.16.05英文标题：Survivorship Needs for Patients With NSCLC Treated With Oral Targeted Therapies中文标题：接受口服靶向治疗的非小细胞肺癌患者的生存需求讲者：Caroline Burley（美国） PT2.17-全球卫生、卫生服务和卫生经济学摘要号：PT2.17.01英文标题：Point-Of-Care Rapid Tissue Diagnosis at Primary Consultation: Optimizing TIME to Treatment in the Neoadjuvant Era中文标题：初次咨询时的即时护理快速组织诊断：优化新辅助治疗时代的治疗时间讲者：Biniam Kidane（加拿大）摘要号：PT2.17.02英文标题：Impact of Timely Treatment Initiation on Outcomes in Non-Small Cell Lung Cancer. a Registry Based Observational Study中文标题：及时开始治疗对非小细胞肺癌疗效的影响，一项基于登记的观察性研究讲者：L. Irving（澳大利亚）摘要号：PT2.17.03英文标题：Impact of Timely Treatment Initiation on Outcomes in Non-Small Cell Lung Cancer. a Registry Based Observational Study中文标题：加速生物衰老与年轻肺癌的发病率和预后不良相关讲者：Y. Liao（中国医学科学院北京协和医学院）摘要号：PT2.17.04英文标题：First Assessment of IASLC Inclusive Practices and Challenges: Results From the Diversity, Equity, and Inclusion Survey中文标题：IASLC 包容性实践与挑战的首次评估：多样性、公平性和包容性调查结果讲者：Narjust Florez（美国）大会日程一览排名不分先后，按照摘要类别划分；如有遗漏或任何问题，请后台留言（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

放射疗法

2025-05-09

·癌度

《癌度早报2025年5月9日》

癌度临床试验病友交流群（点击）一、新药快讯1、国产CDK4/6抑制剂达尔西利新适应症申报上市2025年5月8日，国产CDK4/6抑制剂达尔西利的新适应症申报上市，达尔西利联合内分泌治疗用于激素受体阳性、人表皮生长因子2（HER2）阴性的早期或局部晚期乳腺癌的辅助治疗。这一适应症是基于一项早期临床试验结果，与安慰剂联合内分泌治疗相比，达尔西利联合内分泌治疗可显著降低患者复发风险，提高患者无侵袭性疾病生存期。2、卡替疗法治疗实体瘤，AIC100让半数甲状腺癌患者病情得以控制2025年美国癌症研究协会AACR年会上，美国MD安德森癌症中心的专家报道了一项一期临床研究结果，一款名为AIC100的卡替细胞疗法，在未分化甲状腺癌（ATC）和复发/难治性低分化甲状腺癌（PTDC），表现出令人鼓舞的疗效数据和可接受的安全性。9名治疗的患者，22%患者病灶明显缩小，疾病控制率达到了56%。3、前沿药Tegavivint治疗晚期肝细胞癌疗效可期，疾病控制率63%在2025年美国癌症研究协会AACR年会上，一项早期人体临床试验结果公布，一款名为Tegavivint的新型靶向抗癌药治疗晚期肝细胞癌疗效可期，有11%的患者肿瘤显著缩小或完全消失。疾病控制率达到了63%。该药专注在Wnt/β-catenin信号通路，有望在多种实体瘤展现积极治疗效果。二、抗癌前沿1、个体化mRNA肿瘤疫苗有望今年快速上市近日，个体化mRNA疫苗单药或联合PD-1/CTLA-4双抗、PD-1/VEGF双抗辅助治疗胰腺癌的临床试验在Clinicaltrials.gov网站上注册，新冠疫情以来，个体化mRNA疫苗技术逐渐成熟，基于mRNA技术，研究人员可筛选出这些抗原并进行测序分析，随后通过反向编码设计出对应mRNA序列，进而制备疫苗。目前有多个mRNA疫苗在临床试验阶段，国内企业则是在临床前研发阶段。

AACR会议临床结果疫苗临床1期信使RNA

2024-02-25

·药明康德

穿越血脑屏障、降解大脑靶蛋白近90%的口服蛋白降解剂；使75%患者皮炎完全消退的外用凝胶... | 一周盘点

▎药明康德内容团队编辑本期看点1. 可局部外用的小分子BRAF抑制剂LUT014在早期临床研究中的结果积极，75%患有放射性皮炎的乳腺癌患者的皮炎实现完全消退。2. Arvinas公司开发的首个口服PROTAC蛋白降解剂ARV-102在临床前研究中可使大脑深部的目标蛋白LRRK2降解近90%，其1期临床试验已于近期完成了首例患者给药。3. 口服PI3K/mTOR双抑制剂paxalisib联用放射疗法治疗PI3K通路突变实体瘤的脑转移患者，1期临床试验由于结果积极已提前结束。药明康德内容团队整理LUT014：公布1/2期临床试验数据Lutris Pharma于近日公布了其新型小分子BRAF抑制剂LUT014治疗乳腺癌患者放射性皮炎的1/2期临床试验的积极结果。BRAF抑制剂具有矛盾效应，阻断肿瘤细胞中的该通路会导致细胞凋亡和肿瘤缩小，但阻断正常细胞中的该通路会导致MAPK通路激活，细胞开始生长。LUT014利用的正是这种矛盾效应来增强细胞增殖、平衡细胞破坏，这也是放射性皮炎的典型特征。LUT014是一种可局部外用的凝胶，在该研究中的耐受性良好，可能对2级放射性皮炎有效。在该试验的第一部分中，75%（6/8）患者的放射性皮炎获得了完全消退，即改善至0级皮炎。第二部分的研究结果显示，与安慰剂相比，LUT014组患者的临床相关治疗优势约为30%，患者的生活质量也得到了改善。ARV-102：1期临床试验完成首例患者给药Arvinas公司于近期宣布，其开发的首个口服PROTAC蛋白降解剂ARV-102的1期临床试验已完成首例患者给药。ARV-102旨在降解一种大型多结构域支架激酶LRRK2，拟用于治疗神经退行性疾病。LRRK2活性和表达的增加在遗传上参与多种神经疾病的发病机制，包括帕金森病和进行性核上性麻痹。在非人灵长类动物研究中，ARV-102已被证明可以穿过血脑屏障到达大脑深部区域，并使近90%的LRRK2蛋白降解。Paxalisib：公布1期临床试验数据Kazia Therapeutics公司于近期宣布，基于迄今为止观察到的积极的安全性和良好的临床缓解结果，一项由两部分组成的重要1期试验已提前结束。这项由研究者发起的试验评估了paxalisib（一种口服PI3K/mTOR双抑制剂）联用放射疗法治疗PI3K通路突变实体瘤脑转移患者的效果。在这项研究的第一部分中，paxalisib联用放射疗法在所有9名可评估的患者中均显示出潜在的临床活性迹象。该研究的第二部分也被确认达成主要终点，研究人员还在扩展队列中观察到了令人鼓舞的缓解迹象，这部分的详细结果尚待公布。2023年7月，paxalisib联用放射疗法被美国FDA授予了快速通道资格，用于治疗PI3K通路突变实体瘤脑转移患者。OCU410ST：1/2期临床试验完成首个队列给药Ocugen公司于近期宣布，其针对Stargardt病开发的候选基因疗法OCU410ST的1/2期临床试验已完成首个队列的给药。OCU410ST利用腺相关病毒（AAV）递送平台在视网膜递送RORA基因，可调节与Stargardt病相关的通路，例如脂褐素形成、氧化应激、炎症、细胞存活网络等。RCT2100：1期临床试验开始为首批受试者给药ReCode Therapeutics公司于近期宣布，其在研吸入性mRNA疗法RCT2100的1期临床试验中，第一批健康受试者已开始接受治疗。RCT2100使用了新型选择性器官靶向的脂质纳米颗粒（LNP）递送平台，能够将基因药物高度精确地直接递送至与疾病有关的器官、组织和细胞，从而提高疗效和效力。RCT2100旨在将CFTR mRNA递送至靶细胞并指导它们制造CFTR蛋白的功能版本，从而治疗携带CFTR基因I类突变、对目前批准的CFTR调节剂没有反应的囊性纤维化患者，这类患者在囊性纤维化总患者人群中占约10-13%。ALETA-001：1/2期临床试验完成首例患者给药Aleta Biotherapeutics公司于近期宣布，其潜在“first-in-class” CAR-T细胞接合器ALETA-001的1/2期临床试验已完成首例患者给药。ALETA-001拟用于治疗已接受CD19靶向CAR-T细胞治疗且有失败风险的B细胞恶性肿瘤患者。该疗法通过增加CD19抗原密度和恢复癌细胞上丢失的CD19表达，来提高CD19靶向CAR-T细胞疗法的有效性。ALETA-001含有CD19靶蛋白，该靶蛋白进一步与CD20抗体结构域相连，使得CD19+/CD20+癌细胞很容易被已经在患者体内循环的CD19靶向CAR-T细胞识别并杀死。NPX887：1a/b期临床试验完成首例患者给药NextPoint Therapeutics公司于近期宣布，在治疗表达HHLA2（B7-H7）实体瘤患者的1期临床试验中，首例患者已开始接受其靶向HHLA2的全人源单克隆抗体NPX887的治疗。HHLA2是一种独立于PD-L1的新型免疫检查点和肿瘤靶向抗原，在许多癌症中高表达。NPX887旨在通过阻断与HHLA2结合导致的KIR3DL3介导的免疫抑制来防止实体瘤中的免疫逃逸。NPX887被认为可以促进肿瘤微环境中的T细胞和NK细胞的抗肿瘤活性。Tegavivint：启动1b/2a期临床试验的患者招募Iterion Therapeutics公司于近期宣布，其主打产品tegavivint的1b/2a期临床试验正在招募接受过至少一线系统治疗后失败的晚期肝细胞癌（HCC）患者。Tegavivint是一种有效的选择性小分子，能与Wnt/β-catenin通路中的TBL1结合。TBL1与核β-catenin结合会形成活性转录复合物，从而阻止核β-catenin的核降解，并激活Wnt/β-catenin通路中癌基因的转录。Tegavivint通过与TBL1结合，破坏β-catenin与TBL1之间的相互作用来发挥抗癌作用。除HCC外，Iterion公司正在推进针对多种癌症类型的临床项目，包括非小细胞肺癌、弥漫性大B细胞淋巴瘤和小儿实体瘤等。Shigella4V：公布1/2期临床试验数据LimmaTech Biologics公司公布了其候选四价生物结合疫苗Shigella4V（S4V）的1/2期临床试验的积极中期数据。2023年7月，LimmaTech公司从GSK获得了开发的S4V的许可，该疫苗旨在预防志贺菌（Shigella）引起的志贺菌病。志贺菌病是一种严重的传染病，是致命性腹泻疾病的第二大病因，尤其是在中低收入国家的婴儿中。此次公布的来自472名9个月大婴儿的初步数据证实了S4V具有良好的安全性和耐受性，没有报告与疫苗相关的严重不良事件。S4V对四种最常见的病原体血清型（S. flexneri 2a、3a、6和S. sonnei）具有显著的免疫原性。在第一次或第二次注射后，受试者的血清IgG水平均会有统计学意义上的明显增加，具体取决于所使用的剂量和配方。该结果支持进一步开发，LimmaTech公司计划于2024年启动下一项临床试验。大家都在看药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看）[1] Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease. Retrieved February 21, 2024, from https://www.globenewswire.com/news-release/2024/02/20/2831684/0/en/Arvinas-Announces-First-in-Human-Dosing-of-ARV-102-an-Investigational-PROTAC-Protein-Degrader-for-Neurodegenerative-Disease.html[2] Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers. Retrieved February 21, 2024, from https://ir.monopartx.com/press-releases/detail/81/monopar-receives-clearance-to-proceed-with-first-in-human[3] NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors. Retrieved February 21, 2024, from https://www.businesswire.com/news/home/20240220381798/en[4] Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments. Retrieved February 21, 2024, from https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html[5] Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint. Retrieved February 21, 2024, from https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-early-conclusion-of-clinical-trial-after-reaching-primary-endpoint-302067134.html[6] ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis. Retrieved February 21, 2024, from https://www.businesswire.com/news/home/20240221731121/en[7] Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies. Retrieved February 21, 2024, from https://www.businesswire.com/news/home/20240221259676/en[8] Lutris Pharma Announces Publication of Positive Data From Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer. Retrieved February 21, 2024, from https://www.prnewswire.com/news-releases/lutris-pharma-announces-publication-of-positive-data-from-its-phase-12-trial-of-lut014-to-treat-radiation-dermatitis-in-patients-with-breast-cancer-302066519.html[9] LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V. Retrieved February 22, 2024, from https://www.businesswire.com/news/home/20240222411799/en[10] ONCOC4 ANNOUNCES FIRST PATIENT WITH ADVANCED PROSTATE CANCER DOSED IN PHASE 1/2 TRIAL OF BIONTECH-PARTNERED BNT316/ONC-392 PROGRAM. Retrieved February 22, 2024, from https://www.oncoc4.com/index.php/blog/news-releases/item/19-oncoc4-announces-first-patient-with-advanced-prostate-cancer-dosed-in-phase-1-2-trial-of-biontech-partnered-bnt316-onc-392-program[11] OCUGEN, INC. ANNOUNCES DOSING COMPLETION OF SUBJECTS WITH STARGARDT IN COHORT 1 OF PHASE 1/2 CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF OCU410ST. Retrieved February 22, 2024, from https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-dosing-completion-subjects-stargardt-cohort[12] Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer. Retrieved February 22, 2024, from https://ir.celcuity.com/press-releases/免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床结果放射疗法蛋白降解靶向嵌合体临床1期

100 项与 Tegatrabetan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期肝细胞癌	临床2期	美国	Iterion Therapeutics, Inc.	2023-09-13
晚期肝细胞癌	临床2期	加拿大	Iterion Therapeutics, Inc.	2023-09-13
急性髓性白血病	临床2期	美国	Iterion Therapeutics, Inc.	2023-04-10
复发性骨肉瘤	临床1期	美国	Iterion Therapeutics, Inc.	2026-01-01
难治性骨肉瘤	临床1期	美国	Iterion Therapeutics, Inc.	2026-01-01
惰性B细胞非霍奇金淋巴瘤	临床1期	美国	Ohio State University Comprehensive Cancer Center	2023-03-06
复发性高级别 B 细胞淋巴瘤伴 MYC 和 BCL2 或 BCL6 重排	临床1期	美国	Ohio State University Comprehensive Cancer Center	2023-03-06
难治性弥漫性大B细胞淋巴瘤活化B细胞型	临床1期	美国	Ohio State University Comprehensive Cancer Center	2023-03-06
难治性高级别 B 细胞淋巴瘤	临床1期	美国	Ohio State University Comprehensive Cancer Center	2023-03-06
EGFR突变的非小细胞肺癌	临床1期	美国	Ohio State University Comprehensive Cancer Center	2022-01-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04780568 (NCT04780568, WCLC2025)	临床1期	晚期非小细胞肺癌一线 EGFR sensitive mutation (Ex19del, L858R)	16	Osimertinib+Tegavivint	網構構鹽窪願淵簾艱積(廠範淵鬱艱醖獵齋獵鑰) = 簾壓壓繭廠選鏇觸選襯網製糧憲窪觸構夢願窪 (膚鬱齋獵憲築鏇遞淵餘 ) 更多	积极	2025-09-08
NCT05797805 (ITER-002-HCC, ESMO_GI2025)	临床1/2期	晚期肝细胞癌 APC \| AXIN1 \| CTNNB1	28	Tegavivint 3 mg/kg	遞襯蓋遞襯襯積網積襯(衊網鹽憲衊獵構膚齋蓋) = no cases observed 繭願構齋蓋鹽膚簾鹽網 (獵網廠鹽製糧淵製衊願 ) 更多	积极	2025-07-03
NCT05797805 (ITER-002-HCC, ESMO_GI2025)	临床1/2期	晚期肝细胞癌 APC \| AXIN1 \| CTNNB1	28	Tegavivint 5 mg/kg		积极	2025-07-03
NCT05797805 (AACR2025) 人工标引	临床1/2期	晚期肝细胞癌	22	Tegavivint	獵壓繭醖襯淵構鏇製窪(積鹽齋繭鑰顧衊蓋鏇廠) = hyperbilirubinemia/blood bilirubin increases (n=3), asthenia (n=1), and syncope (n=1). 願齋範糧壓憲鏇蓋築選 (網壓顧積積網艱醖鏇願 ) 更多	积极	2025-04-28
NCT04851119 (PEPN2011, AACR2023) 人工标引	临床1/2期	实体瘤 \| 侵袭性纤维瘤病 \| 淋巴瘤	13	overall	遞選築壓廠夢蓋鏇艱構(齋糧齋範蓋醖鑰鏇範網) = at least possibly related to treatment included anemia (2) and lymphopenia (2). A single patient had a grade 3 QT prolongation requiring cessation of tegavivint after cycle 3. 窪齋壓鹽齋範鹽襯網遞 (夢積觸獵艱糧壓淵範構 ) 更多	积极	2023-04-14
NCT04851119 (PEPN2011, AACR2023) 人工标引	临床1/2期	实体瘤 \| 侵袭性纤维瘤病 \| 淋巴瘤	13	Tegavivint 5 mg/kg		积极	2023-04-14
NCT03459469 (AACR2022) 人工标引	临床1期	侵袭性纤维瘤病	17	BC2059	鹹範夢願餘願糧選窪顧(憲繭醖廠簾鬱築積構網) = 遞餘鏇遞鹽簾築構醖簾蓋鏇遞簾醖餘夢製觸窪 (廠製願構膚鏇範餘壓選 ) 更多	积极	2022-06-15
NCT03459469 (ASCO2022) 人工标引	临床1期	侵袭性纤维瘤病	24	BC2059	範願鹽簾網積憲選簾鹽(製衊夢鹹艱簾鹹鹽鑰膚) = 艱醖觸艱鑰艱鬱艱網齋窪餘窪構夢蓋夢築壓選 (壓餘憲壓廠膚網獵襯鑰 ) 更多	积极	2022-06-02